AbbVie Submits IMBRUVICA® (ibrutinib) Phase III Combination Data to U.S. FDA

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/17/2026

1. GNK
2. SPY
3. PLUR
4. AZN
5. FNGR
6. GSAT
7. S
8. AGPU
9. USO
10. HIVE

Go back to AbbVie Submits IMBRUVICA® (ibrutinib) Phase III Combination Data to U.S. FDA
AbbVie (NYSE: ABBV) Delayed: 249.46 --0 (-0%)
Previous Close $249.46    52 Week High $68.12 
Open $249.46    52 Week Low $50.71 
Day High $249.46    P/E 54.11 
Day Low $249.46    EPS $4.61 
Volume 2,589